Topoisomerase I at the heart of alternative splicing;La topoisomérase I au cœur de l'épissage alternatif

Bulletin du Cancer

Volumn 90, Issue 12, 2003, Pages 1033-1034

  Jeanteur, Philippe ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; IRINOTECAN; PROTEIN KINASE; TOPOTECAN;

CELL PROLIFERATION; GENETIC TRANSFECTION; NOTE; PATHOLOGY; PHOSPHORYLATION;

ALTERNATIVE SPLICING; ANIMALS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; MICE; PHOSPHORYLATION; SRC-FAMILY KINASES;

EID: 0742269862     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. Rivory LP, Robert J. Pharmacology of camptothecin and its derivatives Bull Cancer 1995 ; 82 : 265-85.
2. Pourquier P, Pommier Y. Les topoisomérases I : nouvelles cibles pour le traitement des cancers et mécanismes de résistance. Bull Cancer, Numéro spécial décembre 1998, 5-10.
3. Lavergne O, Bigg DC. The other camptothecins : recent advances with camptothecin analogues other than irinotecan and topotecan. Bull Cancer 1998 ; 58 : 51-8.
4. Lansiaux A, Bailly C. Symphonie pour camptothécines. Bull Cancer 2003 ; 90 : 39-45.
5. Rossi F, et al. Mammalian DNA topoisomerase I specifically posphorylates SR protein splicing factors. Nature 1996 ; 381 : 80-2.
6. Jeanteur P. L'ADN topoisomérase I : une cible double pour les drogues anti-cancéreuses. Bull Cancer 1997 ; 84 : 190.
7. Soret J, et al. Altered protein phosphorylation and exonic enhancer-dependent splicing in mammalian cells lacking topoisomerase I. Cancer Res 2003 ; 63 : 8203-11.
8. Labourier E, et al. Poisoning of topoisomerase I by antitumor indolocarbazole drugs : stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Cancer Res 1999 ; 59 : 52-5.
9. Pilch B, et al. Specific inhibition of serine and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 2001 ; 61 : 6876-84.